Successfully Added to Cart

Updated Cart Total: 0 items Subtotal: $0.00 USD
View Cart

Customers also bought...

    Zymo Research's 100% Satisfaction Guarantee

    Satisfaction Guaranteed

    Read The Zymo Research Promise

    Quick-DNA Urine Kit


    Zymo Research's 100% Satisfaction Guarantee

    Satisfaction Guaranteed

    Read The Zymo Research Promise

    Cat # Name Size
    D3061 Quick-DNA Urine Kit 50 Preps

    Highlights

    • Purify cellular and/or cell-free DNA easily and reliably from up to 40 ml of urine.
    • Uniquely formulated urine conditioning reagent allows stabilization of DNA in urine for up to 1 month at ambient temperature.
    • Zymo-Spin column technology ensures DNA is ready for all sensitive downstream applications including qPCR, DNA sequencing, arrays, and DNA methylation analysis.
    Description & Documents Specifications FAQ Components Citations

    Documents


    Product Description


    The Quick-DNA Urine Kit is an innovative product designed for easy, reliable, and rapid isolation of cellular and/or cell-free DNA from up to 40 ml of urine. The product features a uniquely formulated urine DNA stabilization reagent that also functions as a precipitation reagent. After collection, total (cellular and cell-free) or cell-free urine can be stored at ambient temperature for up to one month by adding the Urine Conditioning Buffer. When ready to extract the urine DNA, just add the Clearing Beads, vortex, and centrifuge to collect the precipitate. Following precipitation, chemical lysis and enzymatic digestion are used to extract DNA from the precipitate. The DNA is subsequently purified and concentrated using Zymo-Spin IC-S Columns. Urine DNA isolated with the Quick-DNA Urine Kit is ideal for qPCR, array, methylation analysis, and other downstream applications.

    Documents

    Technical Specifications

    Applicable For All sensitive downstream applications such as qPCR and Next-Generation sequencing.
    Equipment Centrifuge, microcentrifuge, and heat block/bath.
    Processing Volume ≤ 40 ml
    Purity Typical A260/A280 ≥ 1.8
    Sample Source Urine
    Sample Storage Eluted DNA should be stored at ≤ -20°C.
    Size Range 100 bp - 23 kb
    Type Total DNA including cfDNA
    Yield Up to 5 µg total DNA can be eluted into ≥ 10 µl. 6 - 1000 ng/ml for healthy females. 2 - 20 ng/ml for healthy males.
    Supplemental Info

    Resources


    The Urine Conditioning Buffer (UCB) is necessary if you are interested in isolating cell-free DNA. If omitting the UCB, only cellular DNA is recovered.

    When the Urine Conditioning Buffer is added to the urine, the Clearing Beads helps to create a compact pellet and make it the pellet easy to visualize during the procedure.

    Yes, however, the volume of sample processed becomes large and difficult to handle. In addition, cellular and cell-free DNA cannot be separated. To process urine samples stabilized in DNA/RNA Shield, please contact technical support at tech@zymoresearch.com.

    Remove the oil layer by pipetting and process the pellet. However, residual oil will not affect purification.

    We recommend stabilizing fresh urine with the Urine Conditioning Buffer and storing stabilized urine for later processing. Frozen urine can be processed, however, cells may lyse open upon freeze-thaw, causing in fragmentation of gDNA and resulting in more cell-free DNA than what was originally present.

    Yes, however, we cannot guarantee the efficiency of the Streck preservative.


    Cat # Name Size
    D3004-1-50 Genomic Lysis Buffer 50 ml
    D3061-1-140 Urine Conditioning Buffer 140 ml
    D3004-4-4 DNA Elution Buffer 4 ml
    D3061-2-1 Clearing Beads 1 ml
    D3061-3-20 Urine Pellet Digestion Buffer 20 ml
    D3061-4-10 Urine DNA Prep Buffer 10 ml
    C1001-50 Collection Tubes 50 Pack
    C1015-50 Zymo-Spin IC-S Columns 50 Pack
    D3061-5-12 Urine DNA Wash Buffer 12 ml

    Good yields of DNA in a very simple efficient process.

    - R. W. (Medical University of South Carolina)

    The kit is very useful as it lets us to analyze big volumes without an ultracentrifugation step.

    - S. B.M. (University of Barcelona)

    The protocol was easy to use/follow and it didn't take a great deal of time to get results.

    - S. H. (South College School of Pharmacy)


    DNA was extracted from urinary epithelial cells, non-invasively available tissue, using the Quick-DNATM Urine Kit in study of the Old Order Amish population in the US suspected of having mitochondrial DNA mutations. Collected urine samples were assessed for heteroplasmy level for the m.3243A>G mutation using high-resolution melt (HRM) profiling and confirmed through DNA Sanger sequencing. This finding represents the first report of mitochondrial respiratory chain disorders in the Amish community and suggests that it may be under-diagnosed.

    Lina GG, Amy G, Vockley CW, Dobrowolski SF, Biery A, Irani A, Ibarra J, Morton DH, Mohsen AW, Vockley J. (2016). Mitrocontrial respitory chain disorders in the Old Order Amish population

    Researches used the Quick-DNA Urine Kit (previously known as Extract-all Urine DNA kit) to detect and investigate the role of tumor cell-free DNA copy number variations (CNVs) in urine as clinically relevant diagnostic and predictive biomarkers for metastatic hormone sensitive and metastatic castrate resistant stages of prostate cancer. Urine cfDNAs derived from Quick-DNA Urine Kit were used to perform whole genome sequencing to generate high quality sequencing library. Researchers were able to detect CNVs in all samples, furthermore they were able to detect specific urine cfDNAs genomic aberrations at loci of PTEN, TMPRSS2, AR, and NOTCH1. CNV changes after treatment (androgen deprivation therapy and doxetacel chemotherapy) allowed for the identification of treatment-associated CNV changes, most important of which have been reported to be aberrant in prostate cancer such as copy number changes in RNF43 and ZNRF3 loci and in the LGR4 and MYC proto oncogene loci. These findings could prove potential predictive and prognostic classifiers for advance prostate cancer patients.

    Author Cited

    Need help? Contact Us